OBJECTIVE: Effective antiretroviral therapy (ART) has transformed the care of people with HIV, but it is important to monitor time trends in indicators of treatment success and antic future changes. METHODS: We assessed time trends from 2000 to 2007 in several indicators of treatment success in the UK Collaborative HIV Cohort (CHIC) Study, and using national HIV data from the Health Protection Agency (HPA) we developed a model to project future trends. RESULTS: The proportion of patients on ART with a viral load <50 HIV-1 RNA copies/mL increased from 62% in 2000 to 84% in 2007, and the proportion of all patients with a CD4 count <200 cells/microL decreased from 21% to 10%. During this period, the number of patients who experienced extensive triple class failure (ETCF) rose from 147 (0.9%) to 1771 (3.9%). The number who experienced such ETCF and had a current viral load >50 copies/mL rose fromz 118 (0.7%) to 857 (1.9%). Projections to 2012 suggest sustained high levels of success, with a continued increase in the number of patients who have failed multiple drugs but a relatively stable number of such patients experiencing viral loads >50 copies/mL. Numbers of deaths are projected to remain low. CONCLUSIONS: There have been continued improvements in key indicators of success in patients with HIV from 2000 to 2007. Although the number of patients who have ETCF is projected to rise in the future, the number of such patients with viral loads >50 copies/mL is not projected to increase up to 2012. New drugs may be needed in future to sustain these positive trends.
OBJECTIVE: Effective antiretroviral therapy (ART) has transformed the care of people with HIV, but it is important to monitor time trends in indicators of treatment success and antic future changes. METHODS: We assessed time trends from 2000 to 2007 in several indicators of treatment success in the UK Collaborative HIV Cohort (CHIC) Study, and using national HIV data from the Health Protection Agency (HPA) we developed a model to project future trends. RESULTS: The proportion of patients on ART with a viral load <50 HIV-1 RNA copies/mL increased from 62% in 2000 to 84% in 2007, and the proportion of all patients with a CD4 count <200 cells/microL decreased from 21% to 10%. During this period, the number of patients who experienced extensive triple class failure (ETCF) rose from 147 (0.9%) to 1771 (3.9%). The number who experienced such ETCF and had a current viral load >50 copies/mL rose fromz 118 (0.7%) to 857 (1.9%). Projections to 2012 suggest sustained high levels of success, with a continued increase in the number of patients who have failed multiple drugs but a relatively stable number of such patients experiencing viral loads >50 copies/mL. Numbers of deaths are projected to remain low. CONCLUSIONS: There have been continued improvements in key indicators of success in patients with HIV from 2000 to 2007. Although the number of patients who have ETCF is projected to rise in the future, the number of such patients with viral loads >50 copies/mL is not projected to increase up to 2012. New drugs may be needed in future to sustain these positive trends.
Authors: Alison R McClean; Jason Trigg; Claudette Cardinal; Mona Loutfy; Curtis Cooper; Abigail Kroch; Mostafa Shokoohi; Nimâ Machouf; Réjean Thomas; Marina B Klein; Deborah V Kelly; Alexander Wong; Stephen Sanche; Julio S G Montaner; Robert S Hogg Journal: Can J Hosp Pharm Date: 2022-10-03
Authors: A Gonzalez-Serna; J E Min; C Woods; D Chan; V D Lima; J S G Montaner; P R Harrigan; L C Swenson Journal: Clin Infect Dis Date: 2014-01-14 Impact factor: 9.079
Authors: Margaret May; Mark Gompels; Valerie Delpech; Kholoud Porter; Frank Post; Margaret Johnson; David Dunn; Adrian Palfreeman; Richard Gilson; Brian Gazzard; Teresa Hill; John Walsh; Martin Fisher; Chloe Orkin; Jonathan Ainsworth; Loveleen Bansi; Andrew Phillips; Clifford Leen; Mark Nelson; Jane Anderson; Caroline Sabin Journal: BMJ Date: 2011-10-11
Authors: Andrew N Phillips; Valentina Cambiano; Fumiyo Nakagawa; Alison E Brown; Fiona Lampe; Alison Rodger; Alec Miners; Jonathan Elford; Graham Hart; Anne M Johnson; Jens Lundgren; Valerie C Delpech Journal: PLoS One Date: 2013-02-15 Impact factor: 3.240
Authors: Alan Winston; Alejandro Arenas-Pinto; Wolfgang Stöhr; Martin Fisher; Chloe M Orkin; Kazeem Aderogba; Andrew De Burgh-Thomas; Nigel O'Farrell; Charles Jn Lacey; Clifford Leen; David Dunn; Nicholas I Paton Journal: PLoS One Date: 2013-04-30 Impact factor: 3.240
Authors: David Dolling; Caroline Sabin; Valerie Delpech; Erasmus Smit; Anton Pozniak; David Asboe; Andrew Leigh Brown; Duncan Churchill; Ian Williams; Anna Maria Geretti; Andrew Phillips; Nicola Mackie; Gary Murphy; Hannah Castro; Deenan Pillay; Patricia Cane; David Dunn; David Dolling Journal: BMJ Date: 2012-08-21